Insomnia - the Next DTC Frontier

Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.

John Mack

We accept advertising relevant to the interests of our members.
For more information, see:

Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com

In My Humble Opinion
| Also see Pharma Marketing News OpEd Pieces |

Insomnia - the Next DTC Frontier

Posted: September 29, 2005

You've probably seen ads on TV and in print for several new drugs to treat insomnia. FDA-approved drugs for this condition include AMBIEN (Sanofi-Aventis), LUNESTA (Sepracor), SONATA (King Pharmaceuticals), and ROZEREM (Takeda).
As the competition for market share heats up, you can expect to see these brands push the DTC advertising "envelope" the same way that erectile dysfunction (ED) drug ads did.
Some advertisers may even be in violation of their own promise to abide by PhRMA's voluntary DTC guidelines.
How so?
Read today's post to Pharma Marketing Blog.

| Return to Pharma Marketing Blog Topics |